From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review
Effects of omalizumab in patients with urticaria: uncontrolled studies | |||||
---|---|---|---|---|---|
Author (year) | Urticary type | N | No response | Partial response | Complete response |
Ivyanskiy (2012) | CIU 12, AIU 6, DPU 1 | 19 | 3 | 5 | 11 |
Ferrer (2011) | CSU | 9 | 2 | 5 | 2 |
Groffik (2011) | CSU | 9 | 0 | 4 | 5 |
Sánchez-Machín (2011) | CSU | 1 | 0 | 0 | 1 |
Saavedra (2011) | CSU | 1 | 0 | 0 | 1 |
Krause (2010) | Dermographic U | 1 | 0 | 0 | 1 |
Buller Kotte (2010) | Heat U | 1 | 0 | 0 | 1 |
Binslej-Jensen(2010) | DPU | 1 | 0 | 0 | 1 |
Magerl (2010) | CSU | 8 | 0 | 1 | 7 |
Al-Ahmad (2010) | AIU | 3 | 0 | 0 | 3 |
Kemoli (2010) | AIU | 1 | 0 | 0 | 1 |
Sabroe (2010) | Cholinergic U | 1 | 1 | 0 | 0 |
Waiber (2009) | Solar U | 1 | 0 | 1 | 0 |
Maspero (2009) | AIU | 1 | 0 | 0 | 1 |
Kaplan (2008) | AIU | 12 | 1 | 4 | 7 |
Güzelbey (2008) | Solar U | 1 | 0 | 0 | 1 |
Metz (2008) | Cholinergic U | 1 | 0 | 0 | 1 |
Godse (2008) | CSU | 3 | 0 | 0 | 3 |
Sands (2007) | CAU | 3 | 0 | 0 | 3 |
Spector (2007) | 2 AIU, 1 CSU | 3 | 0 | 0 | 3 |
TOTAL | 78 | 7(8,9%) | 20 (25,6%) | 51 (65,3%) |